Clinical Research Office. A partnership between Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield

Pioneering prostate cancer study marks patient milestone

Researchers are celebrating a major milestone after welcoming their 700th patient to a pioneering prostate cancer study

 

 

  • Researchers have recruited the 700th patient to a pioneering prostate cancer study
  • The study, known as STAMINA, will provide real-world insight into the role supported exercise has in the management of men on ADT therapy
  • If successful, the project could provide a blueprint which can be applied to other cancer and health conditions where exercise has been found to be beneficial.

 

Researchers from Sheffield Teaching Hospitals NHS Foundation Trust are celebrating a major milestone after recruiting the 700th patient to its pioneering STAMINA study, which investigates the role of exercise in improving quality of life and combating the debilitating side effects of hormone treatment for prostate cancer.

The STAMINA (Supported exercise TrAining for Men wIth prostate caNcer on Androgen deprivation therapy) programme, funded by the National Institute for Health and Care Research (NIHR), includes the largest randomised clinical trial in prostate cancer and exercise worldwide.

The £4m project explores the clinical and cost-effectiveness of embedding supervised exercise into the NHS prostate cancer care pathway. It is delivered in partnership with Sheffield Hallam University, Nuffield Health and the Clinical Trials Research Unit at the Leeds Institute for Clinical Trials Research.

To date, 1,656 referrals from 16 NHS Trusts have been processed by the team at Sheffield Hallam University with the final 700th patient recruited this month.

Professor Derek Rosario, Programme Chief Investigator, Consultant Urological Surgeon at Sheffield Teaching Hospitals NHS Foundation Trust and Honorary Professor at Sheffield Hallam University, said: 

“This is a magnificent team achievement, made possible thanks to our many partners: the NHS prostate cancer clinical teams, the research staff at NHS sites and their patients. We are also extremely proud that the research has been delivered to a very high standard, not least because this has been achieved during a time of unprecedented pressure on clinical research activity. We are looking forward to the results with great anticipation.”

Dr Liam Bourke, Professor of Cancer Research at Sheffield Hallam University, said: 

“This is a fantastic achievement from a superb team of researchers. We are very grateful to the NHS for its engagement and the brilliant support we have had from Nuffield Health over the years. A huge thank you also goes to every single patient who has agreed to take part. We simply can’t do this kind of work without such support.”

Professor Ben Kelly, Director of Data at Nuffield Health, said: 

"We all know that physical activity is crucial for staying fit and healthy, and for supporting our mental well-being. However, the benefits of exercise are often overlooked when it comes to the management of long-term health conditions. At Nuffield Health we are committed to building the health of the nation, and we are proud to be a key partner in STAMINA, which will provide incredibly valuable, real-world insight into the role supported exercise has in the management of men on ADT therapy. Today marks an important milestone in the programme, and this takes us another step towards a better evidence base in this area."

Historian, broadcaster and filmmaker David Olusoga OBE joined the STAMINA team at the University this month to discuss the project and offer congratulations on achieving the patient milestone.

David Olusoga OBE said:

"Prostate cancer affects lots of people and it’s great to see that trials like STAMINA are working so hard to get the best outcomes for NHS patients."
 

Androgen deprivation therapy (ADT), a standard treatment for prostate cancer, is associated with significant side effects, including fatigue, depression, sexual dysfunction, cognitive dysfunction (impairment of memory and concentration), increased fat mass and loss of muscle strength. ADT also increases the risk of developing bone fractures, diabetes and heart and circulatory problems. Currently, the only evidence-based treatment to offset the side effects of ADT is via supervised exercise and dietary modification.

The STAMINA pathway of care sees urology and oncology departments recommend exercise to men with prostate cancer in routine clinic appointments and refer men with prostate cancer on ADT to the programme. Patients cannot currently self-refer.

The team at Sheffield Hallam carry out safety checks and tailoring of the intervention before referring men to specifically trained clinical exercise specialists at Nuffield Health. The STAMINA-trained individuals are responsible for delivering the behaviourally-informed STAMINA lifestyle intervention, including one-to-one and small-group supervised programmes tailored to individuals.

If successful, the project could provide a blueprint which can be applied to other cancer and health conditions where exercise has been found to be beneficial.

The results of the STAMINA study are anticipated in early 2025.

ENDS

Photo: Historian, broadcaster and filmmaker David Olusoga OBE (far right) offers congratulations to members of the STAMINA team on reaching their 700th patient milestone